American Journal of Respiratory and Critical Care Medicine · 2011 · 115 citations · 23 references
MedicineClinical SciencesInternal MedicineClinical BiochemistryInflammationPulmonologyChronic Obstructive Pulmonary DiseaseInflammatory BiomarkersObstructive Lung DiseasePulmonary InflammationRespiratory DiseaseBlood-based BiomarkersChronic Obstructive Pulmonary Disease AssessmentChronic Obstructive Pulmonary Disease InflammationChronic Obstructive Pulmonary Disease PathophysiologyHealth Outcomes AnalysisLung Inflammation BiomarkersPrednisolone UseSurrogate Endpoints
RATIONALE: There are no accepted blood-based biomarkers in chronic obstructive pulmonary disease (COPD). Pulmonary and activation-regulated chemokine (PARC/CCL-18) is a lung-predominant inflammatory protein that is found in serum. OBJECTIVES: To determine whether PARC/CCL-18 levels are elevated and modifiable in COPD and to determine their relationship to clinical end points of hospitalization and mortality. METHODS: PARC/CCL-18 was measured in serum samples from individuals who participated in the ECLIPSE (Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints) and LHS (Lung Health Study) studies and a prednisolone intervention study. MEASUREMENTS AND MAIN RESULTS: Serum PARC/CCL-18 levels were higher in subjects with COPD than in smokers or lifetime nonsmokers without COPD (105 vs. 81 vs. 80 ng/ml, respectively; P < 0.0001). Elevated PARC/CCL-18 levels were associated with increased risk of cardiovascular hospitalization or mortality in the LHS cohort and with total mortality in the ECLIPSE cohort. CONCLUSIONS: Serum PARC/CCL-18 levels are elevated in COPD and track clinical outcomes. PARC/CCL-18, a lung-predominant chemokine, could be a useful blood biomarker in COPD.
23
A dendritic-cell-derived C–C chemokine that preferentially attracts naive T cells
Gosse J. Adema, Franca C. Hartgers, Riet Verstraten et al. · Nature · 1997 · 526 citations · Full text